(R)-3-[(S)-phenyl-(2,3,5,6-tetrafluorophenoxy)methyl]pyrrolidine | 1204677-06-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (R)-3-[(S)-phenyl-(2,3,5,6-tetrafluorophenoxy)methyl]pyrrolidine
• 英文别名: (3R)-3-[(S)-phenyl-(2,3,5,6-tetrafluorophenoxy)methyl]pyrrolidine
• CAS: 1204677-06-4
• 化学式: C₁₇H₁₅F₄NO
• 分子量: 325.306
• InChiKey: QLILSXLCYHMHMR-BDJLRTHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-3-[(S)-phenyl-(2,3,5,6-tetrafluorophenoxy)methyl]pyrrolidine 、 三氟乙酸 以 水 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: Synthesis and structure–activity relationships

  摘要：

  A series of 3-(phenoxy-phenyl-methyl)-pyrrolidine analogues were discovered to be potent and balanced norepinephrine (NE) and serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors. Several of these compounds were identified to have suitable in vitro pharmacokinetic properties for an orally dosed and CNS-targeted drug. Compound 39b, in particular, was identified as a potent NET and SERT reuptake inhibitor (NSRI) with minimal off-target activity and demonstrated robust efficacy in the spinal nerve ligation model of pain behavior. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.061
• 作为产物：
  描述：

  (R)-3-((R)-hydroxyphenylmethyl)pyrrolidine-1-carboxylic acid t-butyl ester 在 盐酸 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 18.25h， 生成 (R)-3-[(S)-phenyl-(2,3,5,6-tetrafluorophenoxy)methyl]pyrrolidine
  参考文献：
  名称：

  A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: Synthesis and structure–activity relationships

  摘要：

  A series of 3-(phenoxy-phenyl-methyl)-pyrrolidine analogues were discovered to be potent and balanced norepinephrine (NE) and serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors. Several of these compounds were identified to have suitable in vitro pharmacokinetic properties for an orally dosed and CNS-targeted drug. Compound 39b, in particular, was identified as a potent NET and SERT reuptake inhibitor (NSRI) with minimal off-target activity and demonstrated robust efficacy in the spinal nerve ligation model of pain behavior. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.061

文献信息

• 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS
  申请人：Stangeland Eric

  公开号：US20130178509A1

  公开（公告）日：2013-07-11

  In one aspect, the invention relates to compounds of formula I: where a and R 1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  在一个方面，本发明涉及式I的化合物：其中a和R1-6如规范中定义，或其药学上可接受的盐。式I的化合物是血清素和去甲肾上腺素再摄取抑制剂。在另一个方面，本发明涉及包括这种化合物的制药组合物；使用这种化合物的方法；以及制备这种化合物的过程和中间体。
• US8933249B2
  申请人：——

  公开号：US8933249B2

  公开（公告）日：2015-01-13
• A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: Synthesis and structure–activity relationships
  作者：Lori Jean Van Orden、Priscilla M. Van Dyke、D. Roland Saito、Timothy J. Church、Ray Chang、Jacqueline A.M. Smith、William J. Martin、Sarah Jaw-Tsai、Eric L. Stangeland

  DOI：10.1016/j.bmcl.2012.12.061

  日期：2013.3

  A series of 3-(phenoxy-phenyl-methyl)-pyrrolidine analogues were discovered to be potent and balanced norepinephrine (NE) and serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors. Several of these compounds were identified to have suitable in vitro pharmacokinetic properties for an orally dosed and CNS-targeted drug. Compound 39b, in particular, was identified as a potent NET and SERT reuptake inhibitor (NSRI) with minimal off-target activity and demonstrated robust efficacy in the spinal nerve ligation model of pain behavior. (c) 2012 Elsevier Ltd. All rights reserved.